V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust,J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R.,McGregor, C.G. & Jaffe, A.S. (2004a) Prognosti-cation of survival using cardiac troponins andN-terminal pro-brain natriuretic peptide inpatients with primary systemic amyloidosisundergoing peripheral blood stem cell transplan-tation. Blood, 104, 1881–1887.Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R.,Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca,R., Zeldenrust, S.R., McGregor, C.G. & Jaffe, A.S. (2004b) Serum cardiac troponins and N-ter-minal pro-brain natriuretic peptide: a stagingsystem for primary systemic amyloidosis. Journalof Clinical Oncology, 22, 3751–3757.Gertz, M., Lacy, M., Dispenzieri, A., Hayman, S.,Kumar, S., Buadi, F., Leung, N. & Litzow, M.(2008) Troponin T level as an exclusion crite-rion for stem cell transplantation in light-chainamyloidosis. Leukaemia & Lymphoma, 49,36–41.Jimenez-Zepeda, V.H., Franke, N., Delgado, D.,Winter, A., Stewart, K., Mikhael, J., Reece, D.,Trudel, S., Chen, C. & Kukreti, V. (2010) High-Dose Melphalan for AL Amyloidosis: the Impor-tance of Case Selection to Improve ClinicalOutcomes. Blood, 116, 996. Abstract 2403.Lachmann, H.J., Gallimore, R., Gillmore, J.D.,Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. &Hawkins, P.N. (2003) Outcome in systemic ALamyloidosis in relation to changes in concentra-tion of circulating free immunoglobulin lightchains following chemotherapy. British Journalof Haematology, 122,78–84.Mollee, P., Marlton, P., Mills, A., Bird, R. & Gill,D. (2005) Unexpected hematologic toxicity asso-ciated with the use of intravenous intermediatedose melphalan and dexamethasone in patientswith cardiac AL amyloidosis. Haematologica, 90,202. Abstract PO.1409.Sattianayagam, P., Hawkins, P. & Gillmore, J.(2009) Amyloid and the GI tract. Expert Reviewof Gastroenterology & Hepatology, 3, 615–630.Schey, S.A., Kazmi, M., Ireland, R. & Lakhani, A.(1998) The use of intravenous intermediate dosemelphalan and dexamethasone as inductiontreatment in the management of de novo multi-ple myeloma. European Journal of Haematology,61, 306–310.
[1]
B. Bjerkehagen,et al.
Paratesticular leiomyoma with a der(14)t(12;14)(q15;q24).
,
2011,
Cancer genetics.
[2]
Kenichi Sugihara,et al.
Clinical Significance of High Mobility Group A2 in Human Gastric Cancer and Its Relationship to let-7 MicroRNA Family
,
2008,
Clinical Cancer Research.
[3]
A. Fusco,et al.
Roles of HMGA proteins in cancer
,
2007,
Nature Reviews Cancer.
[4]
A. Ballestrero,et al.
HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22).
,
2007,
Cancer genetics and cytogenetics.
[5]
David P. Bartel,et al.
Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation
,
2022
.
[6]
M. Rocchi,et al.
t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene
,
2006,
Leukemia.
[7]
K. Chada,et al.
Preferential expression of HMGI-C isoforms lacking the acidic carboxy terminal in human leukemia.
,
1998,
Biochemical and biophysical research communications.
[8]
J. Harbott,et al.
12q13, a new recurrent breakpoint in acute non-lymphoblastic leukemia.
,
1995,
Cancer genetics and cytogenetics.
[9]
R. Mayer,et al.
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
,
1994,
The New England journal of medicine.